www.fdanews.com/articles/159602-fda-grants-two-orphan-drug-designations-for-bayers-riociguat
FDA Grants Two Orphan Drug Designations for Bayer’s Riociguat
September 30, 2013
A subsidiary of Bayer has received two orphan drug designations from the FDA for riociguat, which purports to treat pulmonary hypertension and thromboembolic pulmonary hypertension.
Pharmaceutical Business Review
Pharmaceutical Business Review